Literature DB >> 27810933

NMDARs Adapt to Neurotoxic HIV Protein Tat Downstream of a GluN2A-Ubiquitin Ligase Signaling Pathway.

Matthew V Green1, Stanley A Thayer2.   

Abstract

HIV-associated neurocognitive disorder (HAND) affects approximately half of HIV-infected patients. Infected non-neuronal cells release neurotoxic factors such as the viral protein transactivator of transcription (Tat) that potentiate NMDAR function. NMDARs regulate synaptic changes observed after exposure to HIV proteins, which may underlie cognitive impairment in HAND patients. Here, we used patch-clamp recording to measure NMDAR-mediated currents in rat hippocampal cultures after exposure to Tat. Tat (4-16 h) potentiated NMDA-evoked whole-cell current and increased the NMDAR:AMPAR ratio of evoked EPSCs. Potentiated currents adapted back to baseline amplitudes after 24 h of exposure to Tat. Pharmacological inhibition of GluN2A-containing NMDARs prevented adaptation, but inhibition of GluN2B-containing NMDARs did not. Pharmacological and genetic approaches determined that potentiated NMDARs activated the kinase Akt, which then activated the E3 ubiquitin ligase Mdm2. Inhibition of protein synthesis prevented adaptation, suggesting that Mdm2 altered gene expression, possibly through its well known target p53. Expression of GFP-tagged GluN1 subunits resulted in fluorescent puncta that colocalized with synaptic markers. Tat (24 h) caused an Mdm2-dependent loss of NMDAR puncta on a timescale similar to adaption of NMDAR function. Activation of the Mdm2 pathway degrades PSD-95, a scaffolding protein that clusters NMDARs at the synapse and enhances their function. Adaptation to the continued presence of excitotoxins that potentiate NMDARs such as HIV Tat may protect from excessive NMDAR activation while also contributing to the synaptic loss that correlates with cognitive decline in HAND. SIGNIFICANCE STATEMENT: Synaptodendritic damage correlates with cognitive decline in HIV-associated neurocognitive disorder (HAND). In a cell culture model, we show that the HIV protein transactivator of transcription (Tat) initially potentiates NMDARs that then adapt to the presence of the toxin. Adaptation of NMDAR function was mediated by a GluN2A/Akt/Mdm2 pathway not previously linked to neuroinflammatory disorders such as HAND. Activation of this pathway caused a loss of synaptic NMDAR clusters. Decreased NMDAR function may result from a homeostatic response gone awry and underlie impaired synaptic function in HAND.
Copyright © 2016 the authors 0270-6474/16/3612640-10$15.00/0.

Entities:  

Keywords:  Akt; GluN2A; GluN2B; HIV Tat; MDM2; NMDAR

Mesh:

Substances:

Year:  2016        PMID: 27810933      PMCID: PMC5157108          DOI: 10.1523/JNEUROSCI.2980-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  56 in total

1.  Intrahippocampal injections of Tat: effects on prepulse inhibition of the auditory startle response in adult male rats.

Authors:  Sylvia Fitting; Rosemarie M Booze; Ulla Hasselrot; Charles F Mactutus
Journal:  Pharmacol Biochem Behav       Date:  2006-06-21       Impact factor: 3.533

2.  Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss.

Authors:  Hee Jung Kim; Angela H Shin; Stanley A Thayer
Journal:  Mol Pharmacol       Date:  2011-06-13       Impact factor: 4.436

3.  Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse.

Authors:  Amanda N Carey; Elizabeth I Sypek; Harminder D Singh; Marc J Kaufman; Jay P McLaughlin
Journal:  Behav Brain Res       Date:  2011-12-20       Impact factor: 3.332

4.  Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes.

Authors:  Betty Y Zhou; Ying Liu; Byung oh Kim; Yan Xiao; Johnny J He
Journal:  Mol Cell Neurosci       Date:  2004-11       Impact factor: 4.314

5.  The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

Authors:  Edward R Hammond; Rosa M Crum; Glenn J Treisman; Shruti H Mehta; Christina M Marra; David B Clifford; Susan Morgello; David M Simpson; Benjamin B Gelman; Ronald J Ellis; Igor Grant; Scott L Letendre; Justin C McArthur
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

Review 6.  Taking aim at Alzheimer's disease through the mammalian target of rapamycin.

Authors:  Kenneth Maiese
Journal:  Ann Med       Date:  2014-08-08       Impact factor: 4.709

7.  HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes.

Authors:  Eliseo A Eugenin; Jessie E King; Avindra Nath; Tina M Calderon; R Suzanne Zukin; Michael V L Bennett; Joan W Berman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

8.  Akt mediates the anti-apoptotic effect of NMDA but not that induced by potassium depolarization in cultured cerebellar granule cells.

Authors:  Mireille Lafon-Cazal; Virgili Perez; Joël Bockaert; Philippe Marin
Journal:  Eur J Neurosci       Date:  2002-08       Impact factor: 3.386

9.  Activation of α7-containing nicotinic receptors on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses.

Authors:  Xulong Wang; Giordano Lippi; David M Carlson; Darwin K Berg
Journal:  J Neurochem       Date:  2013-09-30       Impact factor: 5.372

Review 10.  Intracerebral hemorrhage injury mechanisms: glutamate neurotoxicity, thrombin, and Src.

Authors:  F Sharp; D Z Liu; X Zhan; B P Ander
Journal:  Acta Neurochir Suppl       Date:  2008
View more
  12 in total

1.  A GluN2B-Selective NMDAR Antagonist Reverses Synapse Loss and Cognitive Impairment Produced by the HIV-1 Protein Tat.

Authors:  Jonathan D Raybuck; Nicholas J Hargus; Stanley A Thayer
Journal:  J Neurosci       Date:  2017-07-17       Impact factor: 6.167

2.  HIV gp120-induced neuroinflammation potentiates NMDA receptors to overcome basal suppression of inhibitory synapses by p38 MAPK.

Authors:  Xinwen Zhang; Matthew V Green; Stanley A Thayer
Journal:  J Neurochem       Date:  2019-01-18       Impact factor: 5.372

3.  Monoacylglycerol lipase inhibitor JZL184 prevents HIV-1 gp120-induced synapse loss by altering endocannabinoid signaling.

Authors:  Xinwen Zhang; Stanley A Thayer
Journal:  Neuropharmacology       Date:  2017-10-20       Impact factor: 5.250

Review 4.  Mechanisms of neuronal dysfunction in HIV-associated neurocognitive disorders.

Authors:  Elena Irollo; Jared Luchetta; Chunta Ho; Bradley Nash; Olimpia Meucci
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 5.  Proteasomal Degradation Machinery: Favorite Target of HIV-1 Proteins.

Authors:  Sneh Lata; Ritu Mishra; Akhil C Banerjea
Journal:  Front Microbiol       Date:  2018-11-21       Impact factor: 5.640

6.  Analysis of Synapses in Cerebral Organoids.

Authors:  Abraam M Yakoub; Mark Sadek
Journal:  Cell Transplant       Date:  2019-06-04       Impact factor: 4.064

Review 7.  The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs.

Authors:  Anna Maria Gorska; Eliseo A Eugenin
Journal:  Front Cell Infect Microbiol       Date:  2020-06-24       Impact factor: 5.293

8.  Modeling HIV-1 neuropathogenesis using three-dimensional human brain organoids (hBORGs) with HIV-1 infected microglia.

Authors:  Roberta S Dos Reis; Shilpa Sant; Hannah Keeney; Marc C E Wagner; Velpandi Ayyavoo
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

9.  HIV-1 Nef-induced lncRNA AK006025 regulates CXCL9/10/11 cluster gene expression in astrocytes through interaction with CBP/P300.

Authors:  Feng Zhou; Xiaomei Liu; Dongjiao Zuo; Min Xue; Lin Gao; Ying Yang; Jing Wang; Liping Niu; Qianwen Cao; Xiangyang Li; Hui Hua; Bo Zhang; Minmin Hu; Dianshuai Gao; Kuiyang Zheng; Yoshihiro Izumiya; Renxian Tang
Journal:  J Neuroinflammation       Date:  2018-10-31       Impact factor: 8.322

10.  Inhibitory Control Deficits Associated with Upregulation of CB1R in the HIV-1 Tat Transgenic Mouse Model of Hand.

Authors:  Ian R Jacobs; Changqing Xu; Douglas J Hermes; Alexis F League; Callie Xu; Bhupendra Nath; Wei Jiang; Micah J Niphakis; Benjamin F Cravatt; Ken Mackie; Somnath Mukhopadhyay; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.